logo

For the Inventor, By the Inventor

Bettingen, Switzerland

Guido Koch

This inventor holds 6 USPTO granted patents and 2 published patent applications and 3 EPO patents. Top assignee: Novartis Ag. Active years: 2005-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Guido Koch. Retrieved from https://idiyas.com/inventor/guido-koch-p6p624dm

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 6 

% Patents Active = 33.3

 

Average Co-Inventor Count = 3.8

ph-index = 1

Forward Citations = 15(Granted Patents)


Location History:

  • Riehen, CH (2005 - 2008)
  • Bettingen, CH (2010 - 2018)
  • Basel, CH (2020)

Company Filing History:

goldMedal6 out of 3,978 
 
Novartis Ag
 patents

Years Active: 2005-2020

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents
1. 10597396 - Beta-lactamase inhibitors (2020-03-24),
2. 10065957 - Beta-lactamase inhibitors (2018-09-04),
3. 9233111 - Pyrrolo pyrimidine derivatives (2016-01-12),
4. 7838674 - Tetracyclic lactame derivatives (2010-11-23),
5. 7470792 - Process for the preparation of epothilone derivatives, new epothilone derivatives as well as new intermediate products for the process and the methods of preparing same (2008-12-30),
6. 6974875 - Process for preparing intermediates for the manufacture of discodermolide and discodermolide analogues (2005-12-13),

Title: Guido Koch: Innovator in Beta-Lactamase Inhibitors

Introduction

Guido Koch is a prominent inventor based in Bettingen, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of beta-lactamase inhibitors. With a total of 6 patents to his name, Koch's work is vital in combating drug-resistant bacterial infections.

Latest Patents

Koch's latest patents focus on compounds that act as beta-lactamase inhibitors. These compounds, described by a specific formula, are designed to be used in combination with beta-lactam antibiotics. This innovative approach aims to treat infections caused by Gram-negative bacteria, including those strains that have developed resistance to conventional treatments.

Career Highlights

Guido Koch is currently associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to further his research and development efforts in the pharmaceutical industry. His contributions have been instrumental in advancing medical treatments and improving patient outcomes.

Collaborations

Koch collaborates with talented professionals in his field, including Anthony Casarez and Markus Furegati. These partnerships enhance the innovative capacity of his projects and contribute to the overall success of their research initiatives.

Conclusion

Guido Koch's work in developing beta-lactamase inhibitors represents a significant advancement in the fight against antibiotic-resistant bacteria. His contributions to Novartis AG and the pharmaceutical industry highlight the importance of innovation in healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…